Recent Posts on This Topic | See All >
[Source: The Arizona Republic] - A Mesa-based company that markets a drug-analysis technology has completed its first examination of an investigational cancer drug being developed by a Canadian biotechnology company.
Predictive Biomarker Sciences, a for-profit company partly owned by Phoenix-based Translational Genomics Research Institute, analyzed a drug candidate being developed by Ottawa, Ontario-based PharmaGap. The analysis suggested that PharmaGap's potential drug, called GAP-107B8, attacks the membrane of colon cancer cells while having less impact on non-cancerous cells.
For more information: Mesa-based Predictive Biomarker Sciences tests cancer drug
Now available: “Action and Impact," a 2014 report on the grant programs and activities of the Flinn Foundation in Arizona biosciences, civic leadership, arts and culture, and the Flinn Scholars program.